Skip to content
Governance Register

← US public companies

MEI Pharma, Inc.

SEC CIK 1262104 · MSHL · last insider filing 2026-06-25

Directors (from insider filings)

NameCapacity as filedFilings
Flynn James P Director filed 2023 - 2026
File Justin J. Director · Secretary, Acting CEO & CFO filed 2023 - 2026
Glover Nicholas Director filed 2013 - 2025
Driscoll Frederick W Director filed 2018 - 2025
Riezman Joshua Director filed 2025 - 2025
Lee Charles Benjamin Director filed 2025 - 2025
Reynolds Thomas C Director filed 2013 - 2025
Wood Steven D Director filed 2023 - 2025
Datoo Taheer Director filed 2023 - 2023
Howson Tamar D Director filed 2019 - 2023
Gold Daniel P PHD Director · President and Chief Executive filed 2010 - 2023
Kango Sujay Director filed 2021 - 2023
Baltic Charles V. III Director filed 2011 - 2023
Urso David M Director · Sr. V.P. and General Counsel filed 2014 - 2023
White Christine Anna Director filed 2010 - 2022
Cohen Cheryl Director filed 2020 - 2022
Clemens Kevan Director filed 2014 - 2021
Rueckert William Dodge Director filed 2008 - 2019
Cann Leah Rush Director filed 2011 - 2016
Williams Bryan Director filed 2006 - 2012
Johnston Philip A Director filed 2009 - 2009
Naughton Christopher Director · CEO & President filed 2008 - 2008

Officers (from insider filings)

NameTitle as filedFilings
Ghalie Richard G Chief Medical Officer filed 2021 - 2023
Drazba Brian G. Chief Financial Officer filed 2017 - 2022
Mass Robert D. Chief Medical Officer filed 2011 - 2020
Zech Thomas M. Chief Financial Officer filed 2010 - 2016
Seaton David R CFO & Secretary filed 2008 - 2008

About this record

From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.

Source: SEC Insider Transactions Data Sets (Forms 3/4/5), US Federal Government public domain.